Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Radiotherapy 299Cisplatin 263Cyclophosphamide 229Doxorubicin 176Paclitaxel 167Vincristine 160Carboplatin 150Filgrastim 139Etoposide 139Gemcitabine 118Fluorouracil 113Docetaxel 112Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 91Leucovorin 90Granulocyte Colony-Stimulating Factor 74Specimen Handling 66Magnetic Resonance Spectroscopy 62Capecitabine 59Irinotecan 58Radiation 54Ifosfamide 51Oxaliplatin 48Daunorubicin 48Temozolomide 47Radiotherapy, Conformal 47Platinum 47Peripheral Blood Stem Cell Transplantation 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Interventional × AMG 337 × Clear all
NCT02344810 2023-05-25

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Withdrawn
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡